A2 Katsausartikkeli tieteellisessä aikausilehdessä
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments (2021)
Hulmi, J. J., Nissinen, T. A., Penna, F., & Bonetto, A. (2021). Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments. Cells, 10(3), Article 516. https://doi.org/10.3390/cells10030516
JYU-tekijät tai -toimittajat
Julkaisun tiedot
Julkaisun kaikki tekijät tai toimittajat: Hulmi, Juha J.; Nissinen, Tuuli A.; Penna, Fabio; Bonetto, Andrea
Lehti tai sarja: Cells
eISSN: 2073-4409
Julkaisuvuosi: 2021
Volyymi: 10
Lehden numero: 3
Artikkelinumero: 516
Kustantaja: MDPI
Julkaisumaa: Sveitsi
Julkaisun kieli: englanti
DOI: https://doi.org/10.3390/cells10030516
Julkaisun avoin saatavuus: Avoimesti saatavilla
Julkaisukanavan avoin saatavuus: Kokonaan avoin julkaisukanava
Julkaisu on rinnakkaistallennettu (JYX): https://jyx.jyu.fi/handle/123456789/74634
Tiivistelmä
Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and increased morbidity and mortality. Anticancer treatments have also been shown to contribute to sustainment or exacerbation of cachexia, thus affecting quality of life and overall survival in cancer patients. Pre-clinical studies have shown that blocking activin receptor type 2 (ACVR2) or its ligands and their downstream signaling can preserve muscle mass in rodents bearing experimental cancers, as well as in chemotherapy-treated animals. In tumor-bearing mice, the prevention of skeletal and respiratory muscle wasting was also associated with improved survival. However, the definitive proof that improved survival directly results from muscle preservation following blockade of ACVR2 signaling is still lacking, especially considering that concurrent beneficial effects in organs other than skeletal muscle have also been described in the presence of cancer or following chemotherapy treatments paired with counteraction of ACVR2 signaling. Hence, here, we aim to provide an up-to-date literature review on the multifaceted anti-cachectic effects of ACVR2 blockade in preclinical models of cancer, as well as in combination with anticancer treatments.
YSO-asiasanat: lihassurkastumasairaudet; syöpähoidot; henkiinjääminen; soluviestintä; proteiinit
Vapaat asiasanat: cancer cachexia; tumor; chemotherapy; myostatin; activins; muscle wasting; survival; mortality; multi-organ
Liittyvät organisaatiot
Hankkeet, joissa julkaisu on tehty
- Riittävä lihasmassa ja aerobinen kunto eliniän pidentäjinä lihaskadossa
- Hulmi, Juha
- Suomen Akatemia
OKM-raportointi: Kyllä
Raportointivuosi: 2021
JUFO-taso: 1